Score Overview
iMedSync
iAI-powered medication adherence platform that reduces hospital readmissions by 40% through real-time patient monitoring and predictive interventions.
- Strong clinical validation with 3 hospital system pilots showing 40% readmission reduction
- Experienced founding team with combined 25+ years in health tech and clinical operations
- Clear regulatory pathway — FDA Class II 510(k) submission planned for Q3 2026
- $1.2M ARR with 180% net revenue retention, growing 15% MoM
Top Priority
iYour biggest vulnerability is the competitive analysis. A well-informed VC will immediately ask about Epic and Cerner building adherence modules into their EHR platforms. Address this head-on with a "Why Point Solution Wins" argument — speed of innovation, clinical specialization, and integration flexibility that platform vendors can't match.
Competitive Landscape: 52/100
Competitive slide is the weakest — 2x2 matrix positions MedSync favorably but feels cherry-picked.
Target: 75+ / 100
Address the EHR platform risk head — on — explain why point solution wins
Critical Red Flags
iTop Strengths
i- Clinical validation data is exceptional — 40% readmission reduction across 3 hospital systems is a strong proof point that few competitors can match
- Founding team has rare combination of deep health tech experience, clinical credibility, and technical AI/ML expertise
- Revenue metrics are strong for the stage — $1.2M ARR with 180% NRR and 15% MoM growth shows product-market fit
- Regulatory strategy is thoughtful — FDA Class II pathway is lower risk than Class III
Priority Fixes
i- 1Rebuild competitive slide with honest positioning and EHR platform risk addressed
- 2Add bottom — up market math to replace generic TAM/SAM/SOM
- 3Break down financial projections into assumption — based model
- 4Create a unit economics slide showing LTV/CAC > 3x
- 5Add a customer case study with quantified outcomes
Radar Analysis
iCONTENT / NARRATIVE — SCORE 72 (Grade B)
Benchmark overlay: Sequoia, YC, a16z, HAX
VISUAL ANALYSIS — SCORE 68 (Grade B-)
Benchmark overlay: Sequoia, YC, a16z, HAX
Content & Narrative
i10-dimension analysis
Problem Statement
82Medication non-adherence framed effectively with $528B annual cost statistic. Hospital readmission angle is compelling.
Solution & Value Prop
78Clear product description with AI-driven monitoring. Value proposition is quantified but needs tighter competitive moat articulation.
Market Opportunity
65TAM/SAM/SOM present but top-down analysis feels generic. Missing bottom-up validation.
Business Model
74SaaS pricing is clear with per-bed model. Unit economics are present but CAC payback period is missing.
Traction & Metrics
88Strong traction slide — $1.2M ARR with 180% NRR is excellent. Clinical outcomes data adds credibility.
Competitive Landscape
52Competitive slide is the weakest — 2x2 matrix positions MedSync favorably but feels cherry-picked.
Team & Founders
85Strong founding team with relevant domain expertise. Advisory board adds credibility. Missing key hire plan.
Financial Projections
58Revenue projections are aggressive without clear assumptions. Missing cash flow and burn rate context.
Ask & Use of Funds
67Raising $12M Series A — amount is reasonable but allocation breakdown lacks specificity.
Storytelling & Design
71Clean deck design with good flow. Slides 8-10 are too dense. Needs stronger opening and closing.
Narrative Flow
iCoherence: 68/100Standard linear arc with strong opening momentum that dips in the middle (market & competition) before recovering with team. Needs a stronger emotional close.
Strong emotional opening with patient story
CMS penalty changes create urgency
Transition from problem to solution could be smoother
Great — proof points right after solution
Jarring shift from strong traction to generic market sizing
Weak positioning after strong business model discussion
Strong team slide rebuilds momentum
Functional but not memorable
Slide Impact Matrix
iScan to view this report on another device
AI-Powered Pitch Deck Analysisv0.17.18
Questions? [email protected]
Like what you see?
Get the same analysis for your pitch deck — from $9 for a Quickscore to $149 for a full VC-Ready Audit.
Analyze My Deck →